Jubaan

Company Overview

Snapshot

Founded in November 2019 by David Rainis, Jubaan is a Health Tech & Life Sciences company with 11–50 employees. The company has raised $3.94M across four funding rounds from four investors. In August 2024, Jubaan secured a grant from the Israel Innovation Authority.

Business overview

Jubaan develops an advanced pre-screening system designed to detect early warning signals of Gastrointestinal disorders, specifically the presence of adenomas in the colon. Leveraging studies of microbiomes found in the oral cavity and on the tongue, the company offers a non-invasive device called Gixam™ for early-stage pre-screening. This technology aims to significantly improve compliance rates for pre-screening exams, thereby transforming the prevention and control of colon cancer. Jubaan operates within the Digital Health and Medical Technologies sector, utilizing artificial intelligence and deep learning to serve the healthcare industry.

Strategic signal

In March 2023, an article highlighted Jubaan's Gixam™ device, emphasizing its potential to save lives through early detection of GI disorders. This signals strong market validation for Jubaan's innovative, non-invasive approach to colon cancer pre-screening, positioning the company as a key player in advancing digital medical diagnostics and improving patient outcomes.

Company Intelligence Q&A

What is Jubaan's core product?

Jubaan's core product is Gixam™, a non-invasive device designed for early-stage pre-screening of Gastrointestinal disorders, particularly for detecting adenomas in the colon.

When was Jubaan founded and by whom?

Jubaan was founded in November 2019 by David Rainis.

Has Jubaan received any grants?

Yes, in August 2024, Jubaan secured a grant from the Israel Innovation Authority.